Literature DB >> 15153496

Random screening of proteins for HLA-A*0201-binding nine-amino acid peptides is not sufficient for identifying CD8 T cell epitopes recognized in the context of HLA-A*0201.

Christian Pelte1, Georgy Cherepnev, Yanjun Wang, Constanze Schoenemann, Hans-Dieter Volk, Florian Kern.   

Abstract

HLA-A2 is the most frequent HLA molecule in Caucasians with HLA-A*0201 representing the most frequent allele; it was also the first human HLA allele for which peptide binding prediction was developed. The Bioinformatics and Molecular Analysis Section of the National Institutes of Health (BIMAS) and the University of Tübingen (Syfpeithi) provide the most popular prediction algorithms of peptide/MHC interaction on the World Wide Web. To test these predictions, HLA-A*0201-binding nine-amino acid peptides were searched by both algorithms in 19 structural CMV proteins. According to Syfpeithi, the top 2% of predicted peptides should contain the naturally presented epitopes in 80% of predictions (www.syfpeithi.de). Because of the high number of predicted peptides, the analysis was limited to 10 randomly chosen proteins. The top 2% of peptides predicted by both algorithms were synthesized corresponding to 261 peptides in total. PBMC from 10 HLA-A*0201-positive and CMV-seropositive healthy blood donors were tested by ex vivo stimulation with all 261 peptides using crossover peptide pools. IFN-gamma production in T cells measured by CFC was used as readout. However, only one peptide was found to be stimulating in one single donor. As a result of this work, we report a potential new T cell target protein, one previously unknown CD8-T cell-stimulating peptide, and an extensive list of CMV-derived potentially strong HLA-A*0201-binding peptides that are not recognized by T cells of HLA-A*0201-positive CMV-seropositive donors. We conclude that MHC/peptide binding predictions are helpful for locating epitopes in known target proteins but not necessarily for screening epitopes in proteins not known to be T cell targets.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15153496     DOI: 10.4049/jimmunol.172.11.6783

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  22 in total

1.  MHC-BPS: MHC-binder prediction server for identifying peptides of flexible lengths from sequence-derived physicochemical properties.

Authors:  Juan Cui; Lian Yi Han; Hong Huang Lin; Zhi Qun Tang; Li Jiang; Zhi Wei Cao; Yu Zong Chen
Journal:  Immunogenetics       Date:  2006-07-11       Impact factor: 2.846

2.  A panel of artificial APCs expressing prevalent HLA alleles permits generation of cytotoxic T cells specific for both dominant and subdominant viral epitopes for adoptive therapy.

Authors:  Aisha N Hasan; Wouter J Kollen; Deepa Trivedi; Annamalai Selvakumar; Bo Dupont; Michel Sadelain; Richard J O'Reilly
Journal:  J Immunol       Date:  2009-07-27       Impact factor: 5.422

3.  Optimal epitope composition after antigen screening using a live bacterial delivery vector: application to TRP-2.

Authors:  Madiha Derouazi; Yan Wang; Raphaël Marlu; Olivier Epaulard; Jean-François Mayol; Nicolas Pasqual; Audrey Le Gouellec; Benoit Polack; Bertrand Toussaint
Journal:  Bioeng Bugs       Date:  2010 Jan-Feb

4.  Mapping of novel peptides of WT-1 and presenting HLA alleles that induce epitope-specific HLA-restricted T cells with cytotoxic activity against WT-1(+) leukemias.

Authors:  Ekaterina Doubrovina; Taissia Carpenter; Dmitry Pankov; Annamalai Selvakumar; Aisha Hasan; Richard J O'Reilly
Journal:  Blood       Date:  2012-05-23       Impact factor: 22.113

5.  Activation-induced expression of CD137 permits detection, isolation, and expansion of the full repertoire of CD8+ T cells responding to antigen without requiring knowledge of epitope specificities.

Authors:  Matthias Wolfl; Jürgen Kuball; William Y Ho; Hieu Nguyen; Thomas J Manley; Marie Bleakley; Philip D Greenberg
Journal:  Blood       Date:  2007-03-19       Impact factor: 22.113

6.  Human Asymptomatic Epitopes Identified from the Herpes Simplex Virus Tegument Protein VP13/14 (UL47) Preferentially Recall Polyfunctional Effector Memory CD44high CD62Llow CD8+ TEM Cells and Protect Humanized HLA-A*02:01 Transgenic Mice against Ocular Herpesvirus Infection.

Authors:  Ruchi Srivastava; Arif A Khan; Sumit Garg; Sabrina A Syed; Julie N Furness; Hawa Vahed; Tiffany Pham; Howard T Yu; Anthony B Nesburn; Lbachir BenMohamed
Journal:  J Virol       Date:  2017-01-03       Impact factor: 5.103

7.  A rationally engineered anti-HIV peptide fusion inhibitor with greatly reduced immunogenicity.

Authors:  Frances Brauer; Kerstin Schmidt; Roland C Zahn; Cornelia Richter; Heinfried H Radeke; Jörn E Schmitz; Dorothee von Laer; Lisa Egerer
Journal:  Antimicrob Agents Chemother       Date:  2012-11-12       Impact factor: 5.191

8.  Comparison of the Cytomegalovirus (CMV) Enzyme-Linked Immunosorbent Spot and CMV QuantiFERON Cell-Mediated Immune Assays in CMV-Seropositive and -Seronegative Pregnant and Nonpregnant Women.

Authors:  Alda Saldan; Gabriella Forner; Carlo Mengoli; Daniel Tinto; Loredana Fallico; Marta Peracchi; Nadia Gussetti; Giorgio Palù; Davide Abate
Journal:  J Clin Microbiol       Date:  2016-03-09       Impact factor: 5.948

9.  Long-term T cell memory to human leucocyte antigen-A2 supertype epitopes in humans vaccinated against smallpox.

Authors:  N D Ostrout; M M McHugh; D J Tisch; A M Moormann; V Brusic; J W Kazura
Journal:  Clin Exp Immunol       Date:  2007-05-04       Impact factor: 4.330

10.  Adoptive transfer of antigen-specific T-cells of donor type for immunotherapy of viral infections following allogeneic hematopoietic cell transplants.

Authors:  Richard J O'Reilly; Ekaterina Doubrovina; Deepa Trivedi; Aisha Hasan; Wouter Kollen; Guenther Koehne
Journal:  Immunol Res       Date:  2007       Impact factor: 2.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.